- Two key presentations by leading KOLs highlight positive
results from aXess trials in adult patients with end-stage renal
disease who need vascular access to hemodialysis
- aXess is a restorative arteriovenous dialysis conduit which
allows vascular access for hemodialysis through the creation of a
new, long-term living vessel
EINDHOVEN, Netherlands,
April 17, 2024 /PRNewswire/
-- Xeltis, a leading developer of transformative implants that
enable the natural creation of living and long-lasting vessels,
announces two presentations on its ground-breaking treatment
options during the 46th Annual Charing Cross Symposium,
the leading symposium in the field of vascular and endovascular
education being held in London
from 23rd-25th April
2024.
Presenter: Dr
Robert Shahverdyan, Head of Vascular
Access Center Hamburg, Germany
Presentation title: Revolutionising haemodialysis
access: Unveiling the latest advancements from the aXess trials
Presentation time: Tuesday 23rd April,
11:00am BST
Dr Shahverdyan will be unveiling the latest results from the
aXess trials, multicentric European single arm studies evaluating
the safety and performance of the aXess graft in subjects older
than 18 years with end-stage renal disease and deemed unsuitable
for fistula creation.
Presenter: Prof
Dr Frans Moll, Department of
Vascular Surgery at the University Medical Center in Utrecht, The Netherlands
Presentation title: Infection Control Prevention: Infectious
challenges, molecular solutions: A glimpse into the future of
vascular conduits through supramolecular chemistry
Presentation time: Thursday 25th April, 10:40am BST
Prof Dr Frans Moll will discuss
how the transformative conduits of supramolecular polymer
technology have the possibility of significantly reducing
infections in multiple clinical applications.
aXessTM is a restorative conduit which enables
the creation of a new, long-term living vessel for hemodialysis
vascular access. It combines the safety and patency of an
arteriovenous fistula (AVF) with the speed to treatment of an
arteriovenous graft (AVG). The aXess vascular access conduit offers
an improved dialysis patient experience and avoids the frequent
reinterventions and complications, such as infections, faced by
renal disease patients.
The conference will be attended by Eliane Schutte, CEO, Paulo Neves, CMO and
Lucien van Os, COO. If you would like to meet with a member of the
team, please get in touch.
About Xeltis
Xeltis is a medtech company developing transformative implants
that enable the natural creation of living and long-lasting
vessels. Xeltis seeks to address the limitations of currently
available options for the millions of people requiring hemodialysis
access grafts or cardiovascular replacements every year. The
Company's proprietary endogenous tissue restoration (ETR) platform
utilizes an advanced polymer implant which regenerates the
patient's own tissue before gradually being absorbed and leaving
new, living and long-lasting vessels in place. Xeltis' most
advanced product currently under clinical development is
aXessTM, an implantable blood vessel for hemodialysis
vascular access. Xeltis' groundbreaking technology has high
potential to be applied to other major vascular and cardiovascular
diseases.
Xeltis is based in The
Netherlands and the USA.
Its investors include DaVita Venture Group, EQT Life Sciences,
Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the
European Innovation Council and Invest-NL, in addition to other
public and private investors.
About aXess
aXess is a restorative conduit which enables the creation of a
new, long-term living vessel for hemodialysis vascular access. It
combines the safety and patency of a fistula with the speed to
treatment of an AV graft. The aXess vascular access conduit offers
an improved dialysis patient experience and avoids the frequent
reinterventions and complications, such as infections, faced by
renal disease patients.
A first-in-human trial of aXess demonstrated a significant
improvement in performance compared to hemodialysis vascular access
solutions. A pivotal trial of aXess is currently enrolling up to
110 patients in nine EU countries.
Go to axesspivotal.com for more details.
View original
content:https://www.prnewswire.co.uk/news-releases/xeltis-announces-latest-results-from-axess-trials-to-be-presented-at-46th-annual-charing-cross-symposium-302118528.html